Document is current
Any future updates will be listed below
-
Authors
Alabi, Shanique
Jaime-Figueroa, Saul
Yao, Zhan
Gao, Yijun
Hines, John
Samarasinghe, Kusal T. G.
Vogt, Lea
Rosen, Neal https://orcid.org/0000-0002-8307-654X
Crews, Craig M. https://orcid.org/0000-0002-8456-2005
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (Gilliam Fellowship)
U.S. Department of Health & Human Services | National Institutes of Health (R50 CA211252-02, R35CA197589)
U.S. Department of Health & Human Services | National Institutes of Health
American Cancer Society
- License Information
-
More Information
Article History
Received: 10 August 2020
Accepted: 14 January 2021
First Online: 10 February 2021
Competing interests
: C.M.C. is a consultant and shareholder in Arvinas, Inc, which provides support to his laboratory. N.R. is on the SAB and owns equity in Beigene, Zai Labs, MAPCure, Ribon and Fortress. N.R. is on the SAB of Astra-Zeneca, Chugai, consults with Novartis, Boehringer Ingelheim, RevMed, Eli Lilly and Array-Pfizer and owns equity in Kura. N.R. receives research support from Boerhinger-Ingelheim, Astra-Zeneca, and RevMed. Other authors do not have competing interests.
